Aptevo Therapeutics Inc. filed an 8-K on September 23, 2026, reporting the final voting results from its Special Meeting of Stockholders held on September 22, 2026, at which four proposals were considered.

Key Highlights

  • Proposal 1 failed: An amendment to the Amended and Restated Certificate of Incorporation received 654,005 votes FOR and 93,851 AGAINST, but was not approved.
  • Proposal 2 approved: Issuance of more than 20% of common stock outstanding as of August 12, 2026, via warrant reload and private placement transactions, was approved with 319,306 votes FOR and 100,098 AGAINST.
  • Proposal 3 approved: The Fifth Amended and Restated 2018 Stock Incentive Plan was approved with 331,590 votes FOR and 82,399 AGAINST.
  • Proposal 4 approved: Authorization to adjourn the Special Meeting passed with 639,823 votes FOR and 92,829 AGAINST.
  • Proxy Statement: All four proposals were described in the definitive proxy statement filed with the SEC on August 31, 2026, according to the filing.

Aptevo Therapeutics 2026 Special Meeting: Four Proposals, Mixed Outcomes

Aptevo Therapeutics Inc. (NASDAQ:APVO), a Delaware corporation headquartered in Seattle, Washington, disclosed the results of its Special Meeting of Stockholders held on September 22, 2026. According to the filing, a quorum was present and stockholders voted on four proposals as described in the company's definitive proxy statement filed with the SEC on August 31, 2026.

Proposal 1, which sought certain "technical and administrative changes" to the company's Amended and Restated Certificate of Incorporation, was not approved despite receiving 654,005 votes FOR compared to 93,851 AGAINST and 4,759 abstentions, with no broker non-votes recorded. The filing does not explain why the proposal failed despite more votes in favor than against, nor does it specify the vote threshold required for approval.

Proposal 2, covering the issuance of more than 20% of the company's issued and outstanding common stock as of August 12, 2026, pursuant to warrant reload and private placement transactions with certain holders under Nasdaq Listing Rule 5635(d), was approved. It received 319,306 votes FOR, 100,098 AGAINST, 4,225 abstentions, and 328,986 broker non-votes. Proposal 3, approving the Fifth Amended and Restated 2018 Stock Incentive Plan, also passed with 331,590 FOR, 82,399 AGAINST, 9,640 abstentions, and 328,986 broker non-votes. Proposal 4, authorizing adjournment of the Special Meeting if necessary or appropriate, was approved with 639,823 FOR, 92,829 AGAINST, and 19,963 abstentions.

What Was Disclosed

Aptevo Therapeutics reported the final vote tallies from its September 22, 2026 Special Meeting. Three of four proposals passed, while the certificate of incorporation amendment was not approved. The 8-K was signed by Daphne Taylor, Senior Vice President and Chief Financial Officer.